Equities analysts forecast that Chimerix Inc (NASDAQ:CMRX) will post ($0.42) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Four analysts have provided estimates for Chimerix’s earnings. The lowest EPS estimate is ($0.45) and the highest is ($0.38). Chimerix reported earnings per share of ($0.37) during the same quarter last year, which would indicate a negative year over year growth rate of 13.5%. The company is scheduled to announce its next earnings report on Wednesday, November 14th.
According to Zacks, analysts expect that Chimerix will report full-year earnings of ($1.66) per share for the current fiscal year, with EPS estimates ranging from ($1.74) to ($1.61). For the next fiscal year, analysts forecast that the company will post earnings of ($1.65) per share, with EPS estimates ranging from ($1.86) to ($1.18). Zacks’ earnings per share averages are an average based on a survey of sell-side research analysts that that provide coverage for Chimerix.
Chimerix (NASDAQ:CMRX) last issued its earnings results on Wednesday, August 8th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.44) by $0.05. Chimerix had a negative net margin of 1,582.64% and a negative return on equity of 34.94%. The company had revenue of $1.19 million for the quarter, compared to analysts’ expectations of $0.94 million.
Shares of Chimerix stock opened at $3.61 on Thursday. Chimerix has a 1 year low of $3.53 and a 1 year high of $5.94. The stock has a market cap of $186.82 million, a price-to-earnings ratio of -2.39 and a beta of 0.91.
Large investors have recently added to or reduced their stakes in the company. Millennium Management LLC raised its position in shares of Chimerix by 12.3% in the 2nd quarter. Millennium Management LLC now owns 284,624 shares of the biopharmaceutical company’s stock valued at $1,355,000 after purchasing an additional 31,091 shares during the last quarter. Opaleye Management Inc. raised its position in shares of Chimerix by 91.7% in the 2nd quarter. Opaleye Management Inc. now owns 1,150,000 shares of the biopharmaceutical company’s stock valued at $5,474,000 after purchasing an additional 550,000 shares during the last quarter. Dimensional Fund Advisors LP raised its position in shares of Chimerix by 7.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 2,481,614 shares of the biopharmaceutical company’s stock valued at $11,812,000 after purchasing an additional 164,472 shares during the last quarter. BlackRock Inc. raised its position in shares of Chimerix by 1.7% in the 2nd quarter. BlackRock Inc. now owns 3,496,177 shares of the biopharmaceutical company’s stock valued at $16,643,000 after purchasing an additional 59,554 shares during the last quarter. Finally, Spark Investment Management LLC purchased a new position in shares of Chimerix in the 2nd quarter valued at approximately $917,000. Institutional investors and hedge funds own 72.98% of the company’s stock.
Chimerix Company Profile
Chimerix, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The company's lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients.
Featured Article: Float
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.